vs
Ginkgo Bioworks Holdings, Inc.（DNA）与MID PENN BANCORP INC（MPB）财务数据对比。点击上方公司名可切换其他公司
MID PENN BANCORP INC的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.9倍（$62.0M vs $33.4M），MID PENN BANCORP INC同比增速更快（30.8% vs -23.8%），MID PENN BANCORP INC自由现金流更多（$71.8M vs $-47.7M），过去两年MID PENN BANCORP INC的营收复合增速更高（21.1% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
该资料实际介绍的是1973年成立于新泽西州切里希尔的商业银行，该银行在2007年被多伦多道明银行收购，并入其旗下的TD Banknorth，之后TD Banknorth统一更名为TD银行。
DNA vs MPB — 直观对比
营收规模更大
MPB
是对方的1.9倍
$33.4M
营收增速更快
MPB
高出54.6%
-23.8%
自由现金流更多
MPB
多$119.5M
$-47.7M
两年增速更快
MPB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $62.0M |
| 净利润 | — | $19.4M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 43.6% |
| 净利率 | — | 31.4% |
| 营收同比 | -23.8% | 30.8% |
| 净利润同比 | — | 47.0% |
| 每股收益（稀释后） | $-1.41 | $0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAMPB
| Q4 25 | $33.4M | $62.0M | ||
| Q3 25 | $38.8M | $61.8M | ||
| Q2 25 | $49.6M | $54.3M | ||
| Q1 25 | $48.3M | $47.7M | ||
| Q4 24 | $43.8M | $47.4M | ||
| Q3 24 | $89.0M | $45.3M | ||
| Q2 24 | $56.2M | $44.1M | ||
| Q1 24 | $37.9M | $42.3M |
净利润DNAMPB
| Q4 25 | — | $19.4M | ||
| Q3 25 | $-80.8M | $18.3M | ||
| Q2 25 | $-60.3M | $4.8M | ||
| Q1 25 | $-91.0M | $13.7M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-56.4M | $12.3M | ||
| Q2 24 | $-217.2M | $11.8M | ||
| Q1 24 | $-165.9M | $12.1M |
营业利润率DNAMPB
| Q4 25 | -211.9% | 43.6% | ||
| Q3 25 | -231.8% | 39.3% | ||
| Q2 25 | -132.1% | 7.9% | ||
| Q1 25 | -184.1% | 35.2% | ||
| Q4 24 | -236.3% | 34.1% | ||
| Q3 24 | -62.0% | 32.8% | ||
| Q2 24 | -396.7% | 32.4% | ||
| Q1 24 | -469.1% | 34.8% |
净利率DNAMPB
| Q4 25 | — | 31.4% | ||
| Q3 25 | -207.9% | 29.6% | ||
| Q2 25 | -121.6% | 8.8% | ||
| Q1 25 | -188.2% | 28.8% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | -63.3% | 27.1% | ||
| Q2 24 | -386.4% | 26.7% | ||
| Q1 24 | -437.3% | 28.7% |
每股收益（稀释后）DNAMPB
| Q4 25 | $-1.41 | $0.83 | ||
| Q3 25 | $-1.45 | $0.79 | ||
| Q2 25 | $-1.10 | $0.22 | ||
| Q1 25 | $-1.68 | $0.71 | ||
| Q4 24 | $-1.91 | $0.72 | ||
| Q3 24 | $-1.08 | $0.74 | ||
| Q2 24 | $-4.23 | $0.71 | ||
| Q1 24 | $-3.32 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $814.1M |
| 总资产 | $1.1B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAMPB
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
股东权益DNAMPB
| Q4 25 | $508.6M | $814.1M | ||
| Q3 25 | $559.8M | $796.3M | ||
| Q2 25 | $613.0M | $775.7M | ||
| Q1 25 | $647.4M | $667.9M | ||
| Q4 24 | $716.1M | $655.0M | ||
| Q3 24 | $797.9M | $573.1M | ||
| Q2 24 | $833.1M | $559.7M | ||
| Q1 24 | $987.3M | $551.0M |
总资产DNAMPB
| Q4 25 | $1.1B | $6.1B | ||
| Q3 25 | $1.2B | $6.3B | ||
| Q2 25 | $1.2B | $6.4B | ||
| Q1 25 | $1.3B | $5.5B | ||
| Q4 24 | $1.4B | $5.5B | ||
| Q3 24 | $1.5B | $5.5B | ||
| Q2 24 | $1.6B | $5.4B | ||
| Q1 24 | $1.6B | $5.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $80.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $71.8M |
| 自由现金流率自由现金流/营收 | -142.8% | 115.8% |
| 资本支出强度资本支出/营收 | 0.0% | 13.3% |
| 现金转化率经营现金流/净利润 | — | 4.12× |
| 过去12个月自由现金流最近4个季度 | — | $132.1M |
8季度趋势，按日历期对齐
经营现金流DNAMPB
| Q4 25 | $-47.7M | $80.0M | ||
| Q3 25 | $-31.6M | $26.3M | ||
| Q2 25 | $-40.3M | $29.0M | ||
| Q1 25 | $-51.5M | $11.5M | ||
| Q4 24 | $-42.4M | $51.4M | ||
| Q3 24 | $-103.5M | $16.9M | ||
| Q2 24 | $-84.4M | $18.0M | ||
| Q1 24 | $-89.3M | $12.4M |
自由现金流DNAMPB
| Q4 25 | $-47.7M | $71.8M | ||
| Q3 25 | — | $24.3M | ||
| Q2 25 | $-40.3M | $27.2M | ||
| Q1 25 | $-59.1M | $8.8M | ||
| Q4 24 | $-56.1M | $44.5M | ||
| Q3 24 | $-118.6M | $16.8M | ||
| Q2 24 | $-111.4M | $17.7M | ||
| Q1 24 | $-96.0M | $12.1M |
自由现金流率DNAMPB
| Q4 25 | -142.8% | 115.8% | ||
| Q3 25 | — | 39.4% | ||
| Q2 25 | -81.2% | 50.1% | ||
| Q1 25 | -122.4% | 18.4% | ||
| Q4 24 | -128.0% | 93.8% | ||
| Q3 24 | -133.2% | 37.1% | ||
| Q2 24 | -198.2% | 40.2% | ||
| Q1 24 | -252.9% | 28.5% |
资本支出强度DNAMPB
| Q4 25 | 0.0% | 13.3% | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 0.1% | 3.2% | ||
| Q1 25 | 15.8% | 5.7% | ||
| Q4 24 | 31.3% | 14.6% | ||
| Q3 24 | 16.9% | 0.0% | ||
| Q2 24 | 48.1% | 0.7% | ||
| Q1 24 | 17.7% | 0.8% |
现金转化率DNAMPB
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 6.08× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
MPB
暂无分部数据
